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Growth differentiation factor 
15 ameliorates nonalcoholic 
steatohepatitis and related 
metabolic disorders in mice
Kook Hwan Kim1, Seong Hun Kim2, Dai Hoon Han3, Young Suk Jo  4, Yong-ho Lee  4 & 
Myung-Shik Lee  1,4
Growth differentiation factor 15 (GDF15) is an endocrine hormone belonging to the TGFβ superfamily 
member. GDF15 administration or GDF15 overexpression has been reported to have anti-obesity and 
anti-diabetic effects. Although non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis 
(NASH) is frequently associated with obesity and insulin resistance, the functional role of endogenous 
GDF15 and therapeutic effect of GDF15 overexpression in NASH and related metabolic deterioration 
have not been evaluated. Here, we found that GDF15 expression was increased in the livers of NASH 
animal models and human subjects with NASH. Elevated expression of GDF15 was due to diet-
induced hepatic endoplasmic reticulum (ER) stress. Gdf15-knockout mice exhibited aggravated NASH 
phenotypes such as increased steatosis, hepatic inflammation, fibrosis, liver injury, and metabolic 
deterioration. Furthermore, GDF15 directly suppressed expression of fibrosis-related genes and 
osteopontin (OPN), contributing factors for NASH-related fibrosis, in hepatic stellate cells in vitro and 
in the liver of mice in vivo. Finally, we found that GDF15-transgenic mice showed attenuation of NASH 
phenotypes and metabolic deterioration. Therefore, our results suggest that induction of endogenous 
GDF15 is a compensatory mechanism to protect against the progression of NASH and that GDF15 
could be an attractive therapeutic candidate for treatment of NASH and NASH-related metabolic 
deterioration.
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide1. NAFLD 
encompasses a pathological spectrum of liver diseases ranging from simple steatosis to non-alcoholic steato-
hepatitis (NASH). NASH is defined as hepatic steatosis with inflammation and fibrosis in the liver, and can pro-
gress to more severe stages such as cirrhosis and hepatocellular carcinoma (HCC)2. NAFLD/NASH is frequently 
accompanied by obesity, dyslipidemia or type 2 diabetes, and thereby NAFLD/NASH patients typically have 
obesity, insulin resistance or diabetes3. Simple steatosis can lead to the development of NASH accompanied by 
inflammation or fibrosis through multiple events including insulin resistance, oxidative stress, endoplasmic retic-
ulum (ER) stress, mitochondrial dysfunction, adipose tissue dysfunction, altered regulation of innate immunity 
or compositional changes of microbiota4. Based on these findings, the “multi-parallel hit” hypothesis has been 
recently proposed to explain the pathogenesis of NASH. Despite growing number of multiple therapeutic targets, 
there are currently no approved pharmacological drugs for treatment of NASH.
Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta (TGFβ) super-
family member and is also known as NAG-1 (nonsteroidal anti-inflammatory drug-activated gene-1), MIC-1 
(macrophage inhibitory cytokine-1), PLAB (placental bone morphogenetic protein) or PTGFB (placental trans-
forming growth factor beta)5–9. GDF15 is widely expressed in various tissues with the highest levels in the liver 
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and placenta5,8,9. Numerous studies suggest that GDF15 is induced by various stimuli such as fatty acids or mito-
chondrial stress10,11. Moreover, GDF15 is implicated in aging and in the development of aging-related patho-
logical diseases such as obesity, cardiovascular diseases, diabetes or cancer12. It has been reported that serum/
plasma GDF15 levels are increased in human subjects with diverse diseases such as cancer13, diabetes14, mito-
chondrial disorders15, cardiac failures16, renal failures17 and chronic liver diseases (chronic hepatitis, cirrhosis and 
HCC)18,19. In addition, recent paper suggest that serum GDF15 level is also increased in human NASH subjects 
with advanced fibrosis20. These results suggest that GDF15 could be used as a potential diagnostic biomarker for 
diverse diseases.
Several studies suggest that exogenous GDF15 exerts protective effects against obesity and insulin resist-
ance11,21,22, although the role of endogenous GDF15 in these diseases has not been clearly shown. However, little 
is known regarding to the functional role of endogenous GDF15 and therapeutic effect of GDF15 overexpression 
in NASH. Here, we observed elevated GDF15 expression in the liver of two different dietary mouse models of 
NASH and human subjects with NASH. We also showed aggravated hepatic steatosis, inflammation, fibrosis and 
metabolic deterioration in Gdf15-knockout (Gdf15−/−) mice fed two different NASH diets, while these pathologic 
and metabolic features were attenuated in GDF15-transgenic (GDF15-Tg) mice. These results suggest that GDF15 
is induced in the liver as a compensatory mechanism to protect against NASH and related metabolic disorders.
Results
GDF15 is upregulated in the livers of mice and human subjects with NASH. To analyze the change 
of hepatic or serum GDF15 expression in NASH animal models, we employed a methionine-choline-deficient 
(MCD) diet model, a widely-used dietary NASH model. When fed MCD diet for 4 or 8 weeks, mice showed 
increased hepatic lipid accumulation and inflammation (Fig. 1a), while whole body and liver weights were 
reduced (data not shown). Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) con-
centrations were also elevated in MCD diet-fed mice (Fig. 1a). Interestingly, we observed significantly increased 
serum GDF15 level in mice fed MCD diet for 4 or 8 weeks compared to control diet-fed mice (Fig. 1b). Moreover, 
Gdf15 gene expression was increased in the liver but not in skeletal muscle, brown adipose tissue or white adipose 
tissue (Fig. 1c), suggesting that increased liver GDF15 expression might contribute to the increase of systemic 
GDF15 level in MCD diet-fed mice. Consistent with a previous report that GDF15 expression was detected only 
in parenchymal cells but not in non-parenchymal cells in the liver5, Gdf15 expression was increased only in 
a hepatocyte cell line but not in a hepatic stellate cell (HSC) line or a Kupffer cell line after exposure to MCD 
media in an in vitro model of NASH (Fig. 1d), suggesting that increased GDF15 expression in hepatocytes might 
contribute to the increases of hepatic Gdf15 expression and serum GDF15 level in MCD diet-induced NASH. 
Serum level and hepatic expression of GDF15 were also elevated in mice fed MCD diet for only 1 week or 2 weeks 
(Fig. 1e,f), suggesting that short-term feeding of MCD diet is sufficient to induce GDF15 expression.
In addition to the results of mouse liver tissues, GDF15 expression was significantly higher in the liver of 
patients with NASH compared to that of control subjects (Fig. 1g). Moreover, microarray transcriptome data 
sets of alcoholic steatohepatitis (ASH)23 revealed that GDF15 expression was elevated in the liver of human ASH 
patients compared to control subjects (Fig. 1h), suggesting that GDF15 is a potential biomarker for a variety of 
steatohepatitis. Taken together, these results suggest that GDF15 expression is induced in the livers of both mice 
and humans with NASH.
MCD diet-induced GDF15 expression is due to ER stress. We next investigated the molecular mech-
anisms underlying GDF15 induction in MCD diet-induced NASH. Since it has been reported that p53 plays an 
important role in pathogenesis of MCD diet-induced NASH24, and that p53 regulates GDF15 expression25, we 
studied the involvement of p53 in GDF15 induction by MCD diet. Consistent with the increased Gdf15 mRNA 
level, GDF15 protein level was also elevated in the livers after MCD diet feeding (Fig. 2a). p53 was also remarkably 
induced in the livers of MCD diet-fed mice (Fig. 2a), in line with a previous report24. However, the p53 inhibitor, 
pifithrin-α did not inhibit MCD diet-induced Gdf15 expression (Supplementary Fig. 1a,b), suggesting that p53 
is not important in hepatic GDF15 induction by MCD diet. Since ER stress has been implicated in the patho-
genesis of NASH26, we studied the contribution of ER stress to MCD diet-induced GDF15 expression. MCD diet 
caused increased expression of ER stress marker proteins, phosphorylated eIF2α, ATF4 and CHOP (also known 
as DDIT3) in the livers (Fig. 2a). When we administered a well-known ER stressor, tunicamycin to mice, serum 
GDF15 level and hepatic Gdf15 expression were higher than those of vehicle-treated mice (Fig. 2b). Treatment 
of HepG2 cells with ER stressors such as tunicamycin or thapsigargin also induced GDF15 expression (Fig. 2c), 
suggesting that ER stress induces hepatic GDF15 expression in vitro as well as in vivo.
To evaluate the molecular mechanism underlying in vivo GDF15 induction by ER stress, we analyzed 
transcriptome data sets of livers from mice with hepatic deletion of eukaryotic translation initiation factor 2 
alpha kinase 3 (Eif2ak3, also known as Perk)27 or ER to nucleus signalling 1 (Ern1, also known as Ire1a) gene28. 
Tunicamycin-induced Gdf15 expression was markedly lower in the liver of hepatocyte-specific Eif2ak3-knockout 
(Eif2ak3Δhep) mice compared to wild-type mice (Fig. 2d), while there was no difference in GDF15 expression 
between hepatocyte-specific Ern1-knockout (Ern1Δhep) and wild-type mice (Fig. 2e). Furthermore, heatmap 
analysis showed that the pattern of Gdf15 expression in Eif2ak3Δhep mice and wild-type mice mirrored that of 
CHOP target genes such as Trib3, Gadd34 (also known as Ppp1r15a), Sars, Wars or Xpot (Fig. 2d). Chop induc-
tion after tunicamycin treatment was also significantly lower in the livers of Eif2ak3Δhep mice but not in the livers 
of Ern1Δhep mice compared to their respective control mice (Fig. 2d,e). Gdf15 induction by ER stressor was also 
much lower in Chop−/− mouse embryonic fibroblasts (MEFs) compared to Chop+/+ MEFs (Fig. 2f). These results 
suggest that PERK-CHOP mediates ER stress-induced GDF15 expression. To study whether ER stress directly 
mediates MCD diet-induced GDF15 expression, we administrated a chemical ER chaperone, 4-phenylbutyric 
acid (4-PBA) to mice. As hypothesized, MCD diet-fed mice treated with 4-PBA showed reduced serum GDF15 
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level and hepatic Gdf15 expression compared to vehicle-treated MCD diet-fed mice, which was accompanied 
by reduced hepatic Chop expression (Fig. 2g). Taken together, our results suggest that ER stress contributes to 
hepatic GDF15 induction in MCD-induced NASH.
Gdf15 deletion aggravates MCD diet-induced NASH in mice. To study the role of GDF15 induction 
in MCD diet-induced NASH, we challenged Gdf15−/− mice with MCD diet. As expected, neither serum GDF15 
level nor hepatic Gdf15 expression was increased in Gdf15−/− mice after MCD diet feeding (Fig. 3a). The decrease 
of body weight caused by MCD diet was significantly less in Gdf15−/− mice compared to wild-type mice (Fig. 3b), 
while food intake was not different between the two groups (Fig. 3c). Intriguingly, loss of liver weight after MCD 
diet was also significantly less in Gdf15−/− mice compared to control mice (Supplementary Fig. 2a). Liver weight 
adjusted for body mass was not decreased but increased in Gdf15−/− mice after MCD diet feeding (Fig. 3d), 
implying that GDF15 modulates liver size in NASH.
Figure 1. GDF15 is induced in the livers of MCD diet-fed mice and human NASH subjects. (a) Liver H&E 
staining and serum ALT/AST levels (n = 8) in C57BL/6 mice fed MCD diet for 4 or 8 weeks. Scale bar, 200 μm. 
Arrows indicate inflammatory loci. (b) Serum GDF15 level in C57BL/6 mice fed MCD diet for 4 or 8 weeks 
(n = 6–8). (c) Relative hepatic Gdf15 mRNA level in C57BL/6 mice fed MCD diet for 4 or 8 weeks (left panel, 
n = 3–5), and relative Gdf15 mRNA level in various metabolic organs in mice fed MCD diet for 8 weeks (right 
panel, n = 5). (d) Relative Gdf15 mRNA levels in Hepa1c1c7, KUP5 or hTERT-HSC cell lines incubated in MCD 
media for 18 h (n = 5). (e,f) Serum GDF15 (e, n = 5) and relative hepatic Gdf15 mRNA levels (f, n = 4–5) in 
mice fed MCD diet for 1 or 2 weeks. (g) Relative GDF15 and COL1A1 mRNA levels in the livers from control 
human subjects and subjects with simple steatosis (SS) or NASH (n = 6). (h) Relative GDF15 and COL1A1 
mRNA levels in the liver tissue from subjects with alcoholic steatohepatitis (ASH, GSE28619) (control, n = 7; 
ASH, n = 15). Data are means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2. ER stress mediates MCD diet-induced GDF15 expression. (a) Immunoblot analysis of liver lysates 
from C57BL/6 mice fed MCD diet for 8 weeks. Asterisk indicates a non-specific band. (b) Serum GDF15 
(left panel, n = 6) and relative hepatic Gdf15 mRNA levels (middle panel, n = 4) in C57BL/6 mice 24 h after 
tunicamycin (Tu, 1 mg/kg) or vehicle (Veh) injection. Time-course of the changes in mouse liver Gdf15 mRNA 
level after Tu injection (right panel, n = 3). (c) Relative GDF15 mRNA level in HepG2 cells after incubation with 
Tu (5 μg/ml) or thapsigargin (Th, 1 μM) for 24 h (n = 3). (d,e) A heatmap showing relative expression of Gdf15 
and upstream or downstream genes of CHOP, and Gdf15/Chop mRNA levels in the livers of Eif2ak3Δhep mice  
(d, GSE29929) and Ern1Δhep mice (e, GSE40515). (f) Relative Gdf15 mRNA level in Chop–/– MEFs treated with 
Th (1 μM) (n = 3). (g) Serum GDF15 (n = 8–9) and relative hepatic Gdf15 or Chop mRNA levels (n = 5) in MCD 
diet-fed C57BL/6 mice treated with 4-PBA (1 g/kg/day) or vehicle (Veh) for 9 days. Data are means ± SEM.  
*p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3. Gdf15 deletion accelerates NASH in mice fed MCD diet for 8 weeks. (a) Serum GDF15 level (left 
panel, n = 5–7) and relative hepatic Gdf15 mRNA level (right panel, n = 3–4). ND indicates not detected. (b) 
Body weight (n = 5–7). (c) Food intake adjusted for body weight (n = 5–7). (d) Liver weight adjusted for body 
weight (n = 5–7). (e) Liver H&E staining. Arrows indicate inflammatory loci. (f) Liver TG content (n = 5–7). 
(g) Masson’s trichrome (MT) staining. (h) Sirius red staining and quantification. (i) αSMA immunostaining 
and quantification. (j) F4/80 immunostaining and quantification. (k) Relative inflammatory gene expression 
(n = 3–4). (l) Serum ALT/AST levels (n = 5–7). Scale bars for H&E, MT and Sirius red staining, 200 μm. Scale 
bars for αSMA and F4/80 immunostaining, 100 μm. Data are means ± SEM. *p < 0.05, **p < 0.01,  
***p < 0.001.
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When we conducted histologic analysis to compare the progression of NASH between Gdf15−/− and wild-type 
mice, the number of inflammatory loci and the size of lipid droplets were apparently increased in the liver of 
Gdf15−/− mice compared to that of control mice after MCD diet feeding (Fig. 3e). As expected, hepatic triglyc-
eride (TG) content was also increased in MCD diet-fed Gdf15−/− mice (Fig. 3f). This change was probably due 
to the reduced expression of β-oxidation-related genes (Acadl and Acadm) (Supplementary Fig. 2b), while the 
expression of fatty acid synthesis-related genes was not altered (Supplementary Fig. 2c). Furthermore, exoge-
nous GDF15 treatment slightly but significantly increased the expression of several β-oxidation-related genes 
in primary hepatocytes but not that of fatty acid synthesis-related genes, fatty acid uptake-related genes or lipo-
lytic genes (Supplementary Fig. 2d), suggesting that increased hepatic lipid accumulation by GDF15 deletion is 
probably due to impaired β-oxidation. Additionally, Masson’s trichrome and Sirius red staining showed aggra-
vated fibrosis in the liver of MCD diet-fed Gdf15−/− mice (Fig. 3g,h). In parallel, Gdf15−/− mice had a signifi-
cantly increased number of alpha-smooth muscle actin (αSMA, also known as ACTA2)-positive cells in the liver 
(Fig. 3i). Furthermore, the number of F4/80 (also known as ADGRE1)-positive macrophages was increased in the 
liver of MCD diet-fed Gdf15−/− mice compared to MCD diet-fed control mice (Fig. 3j), which was accompanied 
by elevated expression of inflammatory genes (Il6, Ccl2) in the liver (Fig. 3k). In contrast, the number of Kupffer 
cells positive for C-type lectin domain family 4, member f (CLEC4F), a specific-Kupffer cell marker29 and Clec4f 
mRNA expression were not different between Gdf15−/− and control mice fed MCD diet (Supplementary Fig. 2e,f), 
suggesting that infiltration of monocyte-derived macrophages is increased in the liver of Gdf15−/− mice probably 
due to increased expression of chemoattractant cytokine such as CCL2. Additionally, serum ALT/AST levels were 
increased in MCD diet-fed Gdf15−/− mice compared to MCD diet-fed controls (Fig. 3l). Taken together, these 
results indicate that endogenous GDF15 induction is a compensatory mechanism to protect against NASH and 
liver damage caused by MCD diet feeding.
Gdf15 deletion accelerates AMLN diet-induced NASH and metabolic deterioration in mice. 
Although MCD diet is widely used to induce NASH in mice, this model has limited value as a model for human 
NASH. Of note, it has been reported that MCD diet-fed mice exhibit remarkable weight loss, low fasting glucose 
and insulin levels, reduced cholesterol and TG levels or increased insulin sensitivity30, which are in contrast to 
those in human subjects with NASH. Thus, we employed Amylin liver NASH (AMLN) diet model as a physiolog-
ically relevant dietary model for human NASH. AMLN diet-fed mice have been recently reported to show met-
abolic characteristics similar to those of human NASH subjects31. To confirm the effect of AMLN diet on NASH 
progression in mice, we fed C57BL/6 mice with standard chow diet (Lab Diet 5053), AMLN diet or matched 
control diet for 30 weeks. AMLN diet-fed mice exhibited aggravation of NASH phenotypes and related meta-
bolic deterioration compared to mice fed matched control diet or standard chow diet (Supplementary Fig. 3a–l). 
Similar results were also observed in C57BL/6 mice fed AMLN diet for 22 weeks (data not shown). Since small 
but significant differences in almost all metabolic parameters were observed between mice fed standard chow diet 
and those fed matched control diet (Supplementary Fig. 3a–l), we employed mice fed AMLN diet and those fed 
matched control diet for all further studies.
In line with the results from MCD diet model, hepatic Gdf15 expression and serum GDF15 level were increased 
in AMLN diet-fed C57BL/6 or Gdf15+/+ mice compared to control diet-fed mice (Fig. 4a,b and Supplementary 
Fig. 4a). Intriguingly, Gdf15–/– mice fed AMLN diet for 30 weeks gained more body and liver weights compared 
to control mice (Fig. 4c and Supplementary Fig. 4b,c) without difference in food intake (Fig. 4d), while there was 
no difference in body weight between Gdf15−/− and control mice fed matched control diet (Fig. 4c). Liver weight 
adjusted for body mass was also increased in AMLN diet-fed Gdf15−/− mice (Fig. 4e), supporting that GDF15 
functions as an inhibitory factor against liver hypertrophy, similar to the results of MCD diet model.
When we conducted histologic analysis to compare the progression of NASH between Gdf15−/− and wild-type 
mice fed AMLN diet, we observed aggravated fibrosis (Fig. 4f,g and Supplementary Fig. 4d), increased infiltration 
of F4/80-positive cells (Fig. 4h and Supplementary Fig. 4e,f), increased expression of inflammatory cytokines 
(Fig. 4h) and increased serum ALT/AST levels (Fig. 4i) in Gdf15−/− mice compared to control mice fed AMLN 
diet for 30 weeks. However, the numbers of CLEC4F-positive Kupffer cells were not different between the two 
groups fed AMLN diet (Supplementary Fig. 4g), supporting that infiltration of monocyte-derived macrophages 
into the liver of AMLN diet-fed mice is modulated by GDF15. Liver TG content of Gdf15−/− mice was also slightly 
but significantly higher than that of control mice after AMLN diet feeding for 30 weeks (Fig. 4j). The difference 
in TG content between Gdf15−/− and control mice was more pronounced after AMLN diet feeding for 12 weeks 
compared to feeding for 30 weeks (Supplementary Fig. 4h), suggesting that ongoing lipid accumulation might 
mask the difference in the lipid accumulation during a long-term feeding of AMLN diet. Although the difference 
in body weight between Gdf15−/− and control mice was less pronounced after AMLN diet feeding for 12 weeks 
compared to feeding for 30 weeks (Fig. 4c), Gdf15−/− mice had significantly higher liver weight adjusted for body 
mass and serum ALT/AST levels after 12 weeks of AMLN diet feeding (Supplementary Fig. 4i,j), suggesting 
that GDF15 acts as an inhibitory factor against liver hypertrophy and could play a protective role against NASH 
regardless of body weight changes. Intriguingly, Gdf15−/− mice fed AMLN diet for 30 weeks also had increased 
fasting glucose/insulin levels and homeostatic model assessment of insulin resistance (HOMA-IR) index com-
pared to control mice (Fig. 4k). Serum cholesterol level was also significantly higher in Gdf15−/− mice compared 
to control mice, while serum free fatty acid (FFA) and TG levels were slightly higher without statistical signifi-
cance (Supplementary Fig. 4k). Cumulatively, our results indicate that GDF15 induction serves as a protective 
mechanism ameliorating AMLN diet-induced NASH and NASH-related metabolic deterioration.
GDF15 suppresses expression of fibrogenic genes in HSCs and NASH livers. We next inves-
tigated the mechanism by which Gdf15 deletion aggravates fibrosis in mice. We found that the expression of 
fibrosis-related genes (Tgfb1, Col1a1, Timp1 and Acta2) was increased in the liver of Gdf15−/− mice compared 
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Figure 4. Gdf15 deletion aggravates NASH and related metabolic parameters in AMLN diet-fed mice.  
(a) Relative hepatic Gdf15 mRNA (n = 5–7) and serum GDF15 levels (n = 7) in C57BL/6 mice fed standard 
chow (Chow), matched control (Con) or AMLN diet (AMLN). (b–k) Serum GDF15 level (b, n = 6–10), body 
weight (c, n = 7–16), food intake adjusted for body weight (d, n = 7–12), liver weight adjusted for body weight  
(e, n = 7–12), liver MT staining (left panel of f), Sirius red staining and quantification (right panel of f),  
quantification of αSMA immunochemistry (g), quantification of F4/80 immunochemistry (left panel of h), 
relative inflammatory gene expression (right panel of h, n = 5–7), serum ALT/AST levels (i, n = 6–9), liver TG 
content (j, n = 6–9), fasting glucose/insulin levels (left and middle panels of k, n = 4–6) and HOMA-IR index 
(right panel of k, n = 4–6) in Gdf15–/– and control mice fed AMLN or control diet for 30 weeks. ND indicates 
not detected. Arrows indicate the time of body weight measurement at 12 weeks and 30 weeks of AMLN diet 
feeding. Scale bars for MT and Sirius red staining, 200 μm. Data are means ± SEM. *p < 0.05, **p < 0.01,  
***p < 0.001.
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to control mice after MCD or AMLN diet feeding (Fig. 5a). To explain these in vivo findings, we investigated the 
in vitro effect of GDF15 on expression of fibrosis-related genes in HSCs, the major source of fibrogenic myofi-
broblasts, since HSCs play a key role in NASH-related fibrosis32. Treatment with 50 or 100 ng/ml recombinant 
GDF15 partially inhibited fibrosis-related gene expression in hTERT-HSCs and primary HSCs treated with TGFβ 
(Fig. 5b,c), although treatment with low doses (0.3–1 ng/ml) of GDF15 had no inhibitory effect on expression of 
fibrotic genes (Fig. 5d). These results suggest that treatment with pharmacological doses of GDF15 might directly 
exert anti-fibrogenic effect on HSCs. Several reports suggest that osteopontin (OPN) (also known as secreted 
phosphoprotein 1, SPP1) is induced in human subjects or mice with NASH33,34, and that OPN aggravates hepatic 
fibrosis in MCD diet-induced NASH mouse model33. Since OPN is upregulated in activated HSCs35, we next stud-
ied the effect of recombinant GDF15 on OPN expression in HSCs. Intriguingly, treatment with pharmacological 
doses of GDF15 suppressed OPN expression in TGFβ-treated hTERT-HSCs and primary HSCs (Fig. 5b,c).
When we investigated the change of OPN expression in the liver of Gdf15−/− mice, expression of Opn gene was 
markedly increased in the liver of Gdf15−/− mice after MCD or AMLN diet feeding (Fig. 5e,f). Furthermore, the 
number of OPN-positive cells was also higher in the liver of Gdf15−/− mice compared to control mice after MCD 
or AMLN diet feeding (Fig. 5e,f). Although OPN is known to be a target gene of Hedgehog signaling pathway 
Figure 5. GDF15 suppresses expression of fibrosis-related genes and OPN in HSCs and NASH livers.  
(a) Relative fibrosis-related gene expression in the liver of Gdf15–/– and control mice fed MCD diet for 8 weeks 
(n = 3–4) or AMLN diet for 30 weeks (n = 5–7). (b–d) Relative expression of fibrosis-related genes in hTERT-
HSCs (b,d) and primary mouse HSCs (c) treated with TGFβ1 (2.5 ng/ml) in the presence or absence of GDF15 
pretreatment. (e,f) Relative Opn mRNA levels and OPN immunostaining in the liver of Gdf15–/– and control 
mice fed MCD for 8 weeks (e, n = 3–4) or AMLN diet for 30 weeks (f, n = 5–7). Scale bars, 100 μm. Data are 
means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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involved in MCD-induced NASH34, we did not observe increased expression of Hedgehog pathway-related genes 
in Gdf15–/– mice after MCD or AMLN diet feeding (Supplementary Fig. 5a,b). Taken together, our findings sug-
gest that GDF15 regulates expression of fibrosis-related genes and OPN in NASH.
GDF15 overexpression alleviates diet-induced NASH and metabolic deterioration in mice. 
Finally, to study whether GDF15 overexpression affects NASH development in the two dietary NASH models, we 
generated liver-specific GDF15-Tg mouse lines expressing human GDF15 (Supplementary Fig. 6a). Among three 
GDF15-Tg mouse lines (14, 19 and 45) showing elevated human GDF15 protein level in serum (Supplementary 
Fig. 6b), we characterized NASH-related metabolic profile in two lines (14 and 45). We did not observe any dif-
ferences in body weight and food intake between GDF15-Tg line 19 and control mice after MCD diet feeding, 
while GDF15 overexpression reduced body weight of mice fed matched control diet (Fig. 6a,b). Importantly, 
GDF15-Tg line 19 mice had reduced expression of inflammatory and fibrotic genes compared to control mice 
fed MCD diet (Fig. 6c). When we employed AMLN diet model also, we found improved NASH and metabolic 
parameters in GDF15-Tg line 19 mice (Fig. 6d–h and Supplementary Fig. 7a–c) despite of increased food intake 
adjusted for body weight (Fig. 6i). Additionally, AMLN diet-fed GDF15-Tg line 19 mice exhibited decreases 
in liver enzyme levels (Fig. 6j), liver weight (adjusted for body weight) (Fig. 6k), and liver TG content (Fig. 6l), 
whereas these parameters were not significantly different between GDF15-Tg line 19 and control mice fed MCD 
diet (Supplementary Fig. 7d–f). Furthermore, GDF15-Tg line 19 mice had reduced hepatic expression of Opn 
gene in two dietary NASH models (Fig. 6m).
We next employed GDF15-Tg line 45 mice to confirm the effect of GDF15 overexpression on NASH. When 
fed MCD diet, GDF15-Tg line 45 mice exhibited attenuated NASH phenotypes such as reduced expression of 
inflammatory and fibrosis-related genes (Supplementary Fig. 8a–f), similar to the results of GDF15-Tg line 19 
mice fed MCD diet. Therefore, these data suggest that GDF15 overexpression leads to improvement of NASH in 
mice.
Discussion
Growing evidence suggests that GDF15 is implicated in pathogenesis of various metabolic disorders such as obe-
sity21, insulin resistance11, myocardial infarction36 and atherosclerosis37,38. Mice with overexpression of GDF15 
exhibited reduced adiposity and improved glucose clearance, which is probably attributable to enhancements 
of thermogenesis and lipid catabolism (lipolysis/β-oxidation), and attenuation of inflammation in adipose tis-
sue, independent on food intake21. Furthermore, administration of recombinant GDF15 improves insulin 
resistance and glucose tolerance by decreasing food intake39–42 or by increasing thermogenesis, lipid catabo-
lism or mitochondrial oxidative phosphorylation without change of food intake11. In addition, GDF15-induced 
beneficial effects on myocardial infraction, atherosclerosis and obesity-related insulin resistance are associated 
with its anti-inflammatory actions such as reduction of neutrophil recruitment to myocardial lesions36 and a 
decrease of macrophage infiltration in atherosclerotic lesions37 and adipose tissue21. Although NAFLD/NASH 
has been reported to be frequently associated with obesity or insulin resistance, to the best of our knowledge, 
the functional importance of GDF15 in NASH and related metabolic disorders has not been evaluated. Here, we 
demonstrated that hepatic GDF15 expression was increased in NASH mouse models. We also observed increased 
GDF15 expression in the liver of human NASH subjects, although large-scale studies are needed to evaluate the 
fundamental clinical importance of GDF15 in NASH. Importantly, we found that Gdf15 deletion exacerbated 
hepatic steatosis, inflammation and fibrosis in NASH animal models using MCD or AMLN diet. Additionally, 
mice with deletion of Gdf15 showed aggravated metabolic parameters such as increased body weight and ele-
vated fasting glucose or insulin level after AMLN diet feeding. These results suggest that endogenous GDF15 
plays a crucial role in attenuating NASH and NASH-related metabolic deterioration in mice. Additionally, we 
showed that GDF15 overexpression led to alleviation of NASH phenotypes in mice. As a possible mechanism 
underlying protective effects of GDF15 on NASH-related fibrosis, we found that treatment with pharmacological 
doses of GDF15 directly suppressed expression of fibrosis-related genes and OPN in HSCs in vitro, although the 
expression of these genes in HSCs treated with physiological/pathological doses (0.3–1 ng/ml) of GDF15 was 
not changed. In addition, we found that GDF15-Tg mice showing supraphysiological serum GDF15 levels also 
had decreased expression of fibrotic genes and OPN in the liver. Notably, mice with deletion of Gdf15 conversely 
showed increased expression of fibrosis-related gene in the liver. Therefore, all these results suggest that GDF15 
could be a promising therapeutic target for treatment of NASH and NASH-related metabolic deterioration.
It has been reported that administration of GDF15 leads to decrease of body weight via reduction of food 
intake in mice22. GDNF family receptor α-like (GFRAL) has recently been identified as a novel receptor for 
GDF15 by four independent groups39–42. In these studies, GFRAL deletion abrogated the effect of GDF15 on body 
weight and food intake. Given that GFRAL is expressed solely in hindbrain neurons but not in peripheral tissues 
in mice40,41, these results suggest that exogenous GDF15 administration leads to resistance to diet-induced obe-
sity via GFRAL-dependent anorexic action in brain. In contrast, we observed the beneficial effect of endogenous 
production or genetic overexpression of GDF15 on NASH progression independent of food consumption. These 
discrepancies in the effect of GDF15 on food consumption might be attributable to differences in experimen-
tal procedures (recombinant GDF15 administration vs. GDF15 overexpression), composition of diets (HFD vs. 
MCD or AMLN diet), duration of diet feeding (1–4 weeks vs. 7–30 weeks) or analytical methods of food intake 
measurement. Furthermore, previous some papers suggest that ALK5-TGFβRII complex also mediates the action 
of GDF15 in various tissues and cells22,36, suggesting the possibility that GDF15 might exert its metabolic effect 
via other receptors as well as GFRAL. Further studies will be necessary to elucidate the in vivo role of GFRAL or 
ALK5-TGFβRII complex in GDF15-induced improvement of NASH.
In the present study, we showed that Gdf15 deletion led to aggravated hepatic steatosis, inflammation and 
fibrosis in mice after NASH diet, while mice overexpressing GDF15 exhibited improvement of these phenotypes. 
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Figure 6. GDF15 overexpression ameliorates NASH phenotypes and related metabolic deterioration in mice. 
(a–c) Body weight (a, n = 3–10), food intake adjusted for body weight (b, n = 3–6), relative inflammatory gene 
expression (left panel of c, n = 3–5) and relative fibrosis-related gene expression (right panel of c, n = 3–5) 
in GDF15-Tg line 19 and control mice fed MCD diet for 7 weeks. (d–l) Body weight (d, n = 4–11), relative 
inflammatory gene expression (left panel of e, n = 4–6), relative fibrosis-related gene expression (right panel of 
e, n = 4–6), fasting glucose level (f, n = 4–11), fasting insulin level (g, n = 4–11), HOMA-IR index (h, n = 4–11), 
food intake adjusted for body weight (i, n = 4–11), serum ALT/AST levels (j, n = 4–11), liver weight adjusted for 
body weight (k, n = 4–11) and liver TG content (l, n = 4–11) in GDF15-Tg line 19 and control mice fed AMLN 
diet for 22 weeks. (m) Relative hepatic Opn mRNA levels in GDF15-Tg line 19 and control mice fed MCD for 7 
weeks (left, n = 3–5) or AMLN diet for 22 weeks (right, n = 4–6). Data are means ± SEM. *p < 0.05, **p < 0.01, 
***p < 0.001.
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We also observed increased fatty acid oxidation in hepatocytes and reduced macrophage recruitment as causes 
of GDF15-induced improvement of steatosis and inflammation. In addition, we showed direct anti-fibrotic effect 
of GDF15 on HSCs, which probably contributes to ameliorated NASH-related fibrosis in mice. The result is in 
line with a recent finding showing the anti-fibrotic effect of GDF15 on alcohol-induced liver injury43. However, 
other recent study has reported that GDF15 treatment increases fibrotic gene expression in HSCs20, which is 
inconsistent with our finding. In that paper, the effect of GDF15 on fibrosis was assessed in HSCs without TGFβ, 
a potent stimulator of fibrosis, while our papers studied the effect of GDF15 on HSCs in the presence of TGFβ. 
Furthermore, we observed that GDF15 alone treatment did not increase expression of fibrotic genes in HSCs. In 
parallel, GDF15-Tg mice did not exhibit increased fibrotic gene expression in the liver after matched control diet 
or regular chow diet. However, given that hepatic lipid accumulation and inflammation trigger fibrotic response 
in the progression of NASH, we cannot exclude the possibility that anti-fibrotic action of GDF15 is partly second-
ary to the reduced hepatic lipid accumulation and inflammation. Thus, further studies are needed to elucidate the 
mechanism underlying GDF15-mediated improvement of NASH-related fibrosis.
In conclusion, our results indicate that GDF15 is induced in NASH livers in a manner dependent on ER 
stress, which serves as a protective mechanism to attenuate hepatic steatosis, inflammation, fibrosis and metabolic 
deterioration. Therefore, our findings provide a new insight regarding the protective role of endogenous GDF15 
in NASH and suggest an innovative therapeutic strategy for treatment of NASH or related metabolic disorders.
Methods
Animal experiments. Gdf15-knockout (Gdf15−/−) and Gdf15+/+ mice have been previously described5. 
Liver-specific GDF15-Tg mice were generated by microinjection of linearized pLiv7-GDF15 into C57BL/6 
zygotes (Macrogen Inc.). pLiv7-GDF15 vector was generated by inserting human GDF15 cDNA into pLiv-7 line-
arized with KpnI and XhoI. Three independent GDF15-Tg mouse founders (lines 14, 19 and 45) were established, 
and metabolic studies were performed employing two mouse lines (19 and 45). C57BL/6 mice were purchased 
from Orient-Bio Laboratory (Korea). Twelve-week-old Gdf15−/− (or GDF15-Tg line 19), 16-week-old C57BL/6 
or 20-week-old GDF15-Tg line 45 mice were fed either MCD diet (Envigo, Teklad Custom Diet, TD.90262) or 
matched control diet (TD.94149). As another dietary NASH mouse model, 5-week-old mice were fed AMLN 
diet comprising 40 kcal% fat, and 20 kcal% fructose and 2% cholesterol (Research Diets, D09100301) or matched 
control diet (10 kcal% fat) with no fructose or cholesterol (D09100304). Food intake was measured every week 
throughout the experimental periods. For in vivo ER stress experiment, mice were injected intraperitoneally 
with 1 mg/kg tunicamycin- or phosphate-buffered saline (PBS)-2% dimethyl sulfoxide (DMSO). For in vivo p53 
inhibition, mice were administrated intraperitoneally with pifithrin-α (2.2 mg/kg, once per day for 7 days) or 
vehicle (5% DMSO, 5% Tween 80 and 90% PBS). For in vivo treatment with a chemical ER chaperone, mice were 
given 4-PBA (1 g/kg/day) in drinking water for 9 days. Male mice were used in all experiments. All animals were 
housed in individual ventilated cages (maximum of 5 mice per cage) under an environmentally controlled room 
(22 °C, 12 h light/dark cycle) with free access to food and water. All animals were maintained in a specific patho-
gen free (SPF) facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal 
Care International (AAALAC). All animal experiments were approved by the Institutional Animal Care and Use 
Committee of Yonsei University Health System (IACUC of YUHS) and were conducted in accordance with the 
guidelines of IACUC of YUHS.
Human NAFLD samples. Liver tissues were from 18 subjects (6 normal subjects, 6 subjects with simple 
steatosis and 6 subjects with NASH) who underwent hepatectomy at Severance Hospital due to primary liver can-
cer or metastatic (secondary) liver cancer. Clinical characteristics of all subjects are described in Supplementary 
Table 1. The non-tumor areas were isolated and used for RNA analysis. Liver histology was assessed by an expe-
rienced pathologist according to a diagnostic criteria44, and classified into three groups: normal, simple steatosis 
and NASH. Diagnostic criteria for NASH included the presence of biopsy-proven steatosis, ballooning, lobular 
inflammation and/or fibrosis without history of alcohol intake (<210 g/week for men and 140 g/week for women) 
and hepatitis B or C virus infection. Written informed consent was obtained from all subjects. This protocol 
and study were approved by the Institutional Review Board of Severance Hospital, Yonsei University College of 
Medicine. All experiments were performed in accordance with relevant guidelines and regulations.
Transcriptome analyses. All transcriptomic data were from publicly available Gene Expression Omnibus 
(GEO) repository. To analyze the change of GDF15 expression in ASH, gene microarray data sets of the liv-
ers of human subjects with ASH (accession number GSE28619)23 were downloaded from the GEO database. 
Microarray data sets of the livers of hepatocyte-specific Eif2ak3-knockout mice27 and hepatocyte-specific 
Ern1-knockout mice28 from GEO repository were also used to evaluate the effect of PERK or IRE1α pathway on 
tunicamycin-induced GDF15 expression (GSE29929 and GSE40515). Heatmap analyses were conducted using 
GENE-E software (The Broad Institute).
Reagents. 4-PBA, pifithrin-α, tunicamycin, thapsigargin and DMSO were purchased from Sigma. 
Recombinant human TGFβ1 and human GDF15 were purchased from Peprotech and Biovision, respectively.
Cell culture. HepG2 and Hepa1c1c7 cells were obtained from the American Type Culture Collection. CHOP 
MEFs were provided by R Kaufman. Human hepatic stellate cell line (hTERT-HSC) was kindly provided by D 
Brenner and WI Jeong45. Mouse Kupffer cell line (KUP5) was obtained from the RIKEN BioResource Center46. 
Primary mouse hepatocytes were isolated from 20-week-old Gdf15 wild-type mice by collagenase digestion and 
Percoll density gradient method. Primary mouse HSCs were isolated from 20-week-old Gdf15 wild-type mice 
using a previously described protocol with some modifications47. Briefly, the liver was perfused consecutively 
with EGTA, pronase (Sigma) and collagenase D (Sigma) solutions, and then was further digested with pronase/
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collagenase solution with DNase I (Sigma). HSCs were isolated by OptiPrep (Sigma) density gradient centrifu-
gation. The purity of HSCs was assessed by retinol autofluorescence and appearance of lipid droplets. Cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum and 1% antibi-
otics (penicillin-streptomycin-amphotericin B) at 37 °C in a humid atmosphere of 5% CO2. All cells were free of 
mycoplasma contamination. For analysis of GDF15 expression in an in vitro NASH model, Hepa1c1c7, KUP5 and 
hTERT-HSC cells were seeded at 6-well plates, incubated for 24 h and maintained in serum-free DMEM for 24 h. 
Cells were then incubated in MCD medium (WelGENE Inc.) or control DMEM for 18 h. To analyze fibrotic gene 
expression, serum-starved hTERT-HSCs and primary mouse HSCs were pre-treated with recombinant GDF15 
(0.3, 1, 50 or 100 ng/ml) for 30 min, and then were incubated with recombinant TGFβ1 (2.5 ng/ml) for 18 h.
RNA analysis. Total RNA was isolated from various cells or liver tissues using Hybrid-R or RibospinTM II Kit 
(GeneAll Biotechnology) according to the manufacturer’s instruction. cDNA was synthesized from 2 μg of total 
RNA using Moloney Murine Leukemia Virus (MMLV)-reverse transcriptase (Promega) and oligo(T) primer at 
42 °C for 1 h. An aliquot (1/160 vol) of the cDNA was then subjected to PCR amplification using mouse or human 
gene-specific primers (Supplementary Table 2). Real-time RT-PCR was conducted using SYBR Green Master 
Mix (Takara) in a QuantStudio 3 Real-Time PCR machine (Applied Biosystems). The relative expression values 
of specific genes were normalized to that of RPL32 (Rpl32) mRNA.
Immunoblot analysis. Immunoblotting was performed as previously described48. Tissues and cultured 
cells were lysed in radio-immunoprecipitation assay (RIPA; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% 
sodium deoxycholate, 1 mM EDTA, 1% (v/v) NP-40) buffer supplemented with 1 mM PMSF and a protease 
inhibitor cocktail (Roche) for 30 min on ice. Protein extracts were obtained by centrifugation at 18,000 × g for 
20 min at 4 °C. Protein concentrations were measured by the Bradford method using Bio-Rad Protein Assay Dye 
Reagent (Bio-Rad). Proteins in the lysates were separated on SDS/PAGE gels (7–12%) or NuPAGE Bis-Tris Gels 
(ThermoFisher), and transferred to PVDF membranes (Millipore). Membranes were then incubated with anti-
bodies against HSP90 (sc-7947; Santa Cruz Biotechnology, 1:5000 dilution), ATF4 (#11815; Cell Signaling, 1:1000 
dilution), total eIF2α (#9722; Cell Signaling, 1:2000 dilution), phospho-eIF2α (#3597; Cell Signaling, 1:1000 dilu-
tion), CHOP (sc-7351; Santa Cruz Biotechnology, 1:1000 dilution), GDF15 (sc-10607; Santa Cruz Biotechnology, 
1:1000 dilution) or p53 (OP03; Millipore, 1:1000 dilution) in Tris-buffered saline with 0.05% Tween-20 (TBST) 
containing 5% (w/v) non-fat dry milk. After incubation of membranes with horseradish peroxidase-conjugated 
secondary antibodies, immunoreactive protein bands were visualized using EZ-Western Lumi Femto ECL solu-
tion (DoGen).
Histology and staining analysis. Liver tissues were harvested and immediately fixed with 10% neutral 
buffered formalin (Sigma) to make paraffin-embedded blocks. Hematoxylin and eosin (H&E) staining, Sirius 
red staining, Masson’s trichrome staining and immunohistochemistry were conducted using paraffin-embedded 
tissue sections. For immunohistochemistry, liver sections were stained with antibodies against αSMA (ab5694; 
Abcam, 1:150 dilution), F4/80 (ab6640; Abcam, 1:100 dilution), osteopontin (AF808; R&D Systems, 1:100 dilu-
tion) or CLEC4F (AF2784; R&D Systems, 1:200 dilution). For quantification for immunohistochemical staining, 
stained slides were scanned using an Aperio Scanscope AT Turbo instrument (Aperio Technologies) and analyzed 
using ImageScope software (Aperio Technologies). For all analyses, 20 randomly chosen fields from at least 4–5 
sections per group were quantified using NIH ImageJ software.
Blood chemistry and metabolite analysis. Glucose levels in blood samples obtained from tail vein were 
measured with an Accu-Check glucometer (Roche). Serum insulin level was determined with a Mouse Insulin 
ELISA Kit (Shibayagi). Serum ALT, AST, TG and cholesterol levels were measured with a Fuji Dri-Chem 3500 
biochemistry analyzer (Fujifilm). Serum GDF15 level was determined using a Mouse GDF-15 DuoSet ELISA Kit 
(R&D Systems) or a Human GDF-15 Quantikine ELISA Kit. Serum FFA level was determined using a SICDIA 
NEFAZYME Kit (Shinyang Chemical). Liver TG content was measured using a Triglyceride Kit (GPO-Trinder, 
Sigma). HOMA-IR index was calculated according to the following formula: [fasting insulin (μlU/ml) × fasting 
glucose (mg/dl)]/405.
Statistical analysis. All values are expressed as means ± SEM. Statistical significance was tested with an 
unpaired two-tailed Student’s t test to compare two groups and one-way analysis of variance (ANOVA) with a 
post-hoc Newman-Keuls test to compare multiple groups. All analyses were performed using GraphPad Prism 
Version 6 software (La Jolla, CA, USA). P values less than 0.05 were considered to indicate statistically significant 
differences.
Data availability. All data generated or analyzed during this study are available from the corresponding 
author on reasonable request.
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